Ztalmy® (ganaxolone) – New orphan drug approval
March 18, 2022 - Marinus Pharmaceuticals announced the FDA approval of Ztalmy (ganaxolone), for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older.
Download PDF
